Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award
17. November 2023 02:00 ET
|
Verona Pharma plc
Verona Pharma plc announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023' at the SCRIP awards.
Verona Pharma Announces November 2023 Investor Conference Participation
08. November 2023 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at...
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
02. November 2023 03:04 ET
|
Verona Pharma plc
US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference...
Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update
19. Oktober 2023 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023
06. Oktober 2023 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it will hold an Investor Update in New York City for...
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023
03. Oktober 2023 02:00 ET
|
Verona Pharma plc
PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON...
Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD
11. September 2023 02:00 ET
|
Verona Pharma plc
PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a decade LONDON and...
Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023
06. September 2023 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces an oral presentation on an additional analysis from its...
Christina Ackermann Joins Verona Pharma as Non-Executive Director
31. August 2023 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces effective September 1, 2023, Ms. Christina Ackermann will join the board as...
Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
03. August 2023 02:00 ET
|
Verona Pharma plc
NDA submitted to US FDA for ensifentrine for maintenance treatment of COPD Phase 3 ENHANCE data published in the American Journal of Respiratory and Critical Care Medicine Strong balance sheet to...